FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20049		

OMB APPRO	JVAL						
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol Evelo Biosciences, Inc. [EVLO]										k all appli	tionship of Reporting all applicable) Director		g Person(s) to Issuer 10% Owner	
	•	CIENCES, INC.	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/31/2022									Officer below)	(give title		Other (s below)	pecify	
(Street)			02139		4. If							Line)	Individual or Joint/Group Filing (Check Applicable) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)		-										Feisoi				
		Tab	le I - Noi	n-Deriv	ative	Sec	curiti	ies Ac	quired	, Dis	posed o	of, or B	enefi	cially	Owned	d			
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		ar) E	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispo		Dispose	ities Acqu d Of (D) (Ir		4 and Securiti Benefic Owned		es ally Following	Form	: Direct 0 Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) (D)	PI	rice	Reported Transact (Instr. 3	tion(s)			
Common Stock 0			01/31	/2022	/2022		M ⁽¹⁾		2,052	2 A	1)	\$ <mark>0</mark>	49,306			D			
Common	Stock			01/31	/2022				M ⁽¹⁾		2,873	3 A	1)	\$ <mark>0</mark>	50 52,179 D				
		Т	able II -								osed of converti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date, Trans			of E		Expiration	6. Date Exercisa Expiration Date Month/Day/Yea		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		S (1	8. Price of Derivative Gecurity Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amo or Num of Shar	ber					
Restricted Stock Units	\$0.0	01/31/2022			M			2,052	(2)		(2)	Commor Stock	2,0	52	\$0	10,263		D	

Explanation of Responses:

\$0.0

- 1. Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person.
- 2. The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates.

2,873

(3)

3. The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates

Remarks:

Restricted

Stock

/s/ Daniel S. Char, Attorney-in-Fact for David R. Epstein

2,873

\$<mark>0</mark>

01/31/2022

14,367

D

** Signature of Reporting Person

Commo

Stock

(3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

01/31/2022

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.